Patient confidence and safety concerns during the COVID-19 pandemic will likely quicken the transition of ophthalmic procedures away from hospital settings to ASCs, according to a speaker during an Eyecelerator LiveStream presentation.
“Trends were already shifting out of the hospital OR over to ambulatory surgery centers and will more than likely be accelerated because of this pandemic,” Nancy Lurker, EyePoint Pharmaceuticals president and CEO, said during the event.
In the second of a series of events hosted by Eyecelerator, several ophthalmic industry leaders discussed their
Uncategorized